JAMA|2025|Kushner R, Almandoz J, Rubino D|10 citations
PMID: 40728833
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIM: - To describe baseline characteristics and safety data of real-world use of semaglutide 2.4 mg. METHODS: - Patients with a body mass index (BMI) ≥40 kg/mand at least one of the following treated weight-related comorbidities (WRC: hypertension, d…
BACKGROUND: Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. METHODS: In a 71-week, double-blind, rando…
There are different molecular pathways that regulate appetite, particularly the role of the hypothalamus, circadian rhythms, and gastrointestinal peptides. The hypothalamus integrates signals from orexigenic peptides like neuropeptide Y (NPY) and ago…
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a highly prevalent metabolic disorder with increasing global incidence, linked to gut microbiota dysbiosis. This study investigated the effects of semaglutide, a long-acting GLP-1 receptor agonist, on gu…
Polycystic ovarian syndrome (PCOS) is one of the chief causes of infertility in women of reproductive age. Several drugs belonging to the oral contraceptive class have been approved for the treatment of PCOS. Nonetheless, the capability to target onl…
AIM: To estimate the impact of semaglutide 2.4 mg treatment on the risk of major adverse cardiovascular events (MACE) in adults with overweight/obesity in the United States based on the SELECT trial of patients with atherosclerotic cardiovascular dis…
INTRODUCTION: Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist has shown significant promise in weight reduction and glycemic management in patients with type 2 diabetes (T2DM). Howev…
Background Incretin-based therapies have emerged as effective strategies for obesity and type 2 diabetes mellitus (T2DM) management. Semaglutide and tirzepatide are among the most promising agents. Real-world data in Bangladesh on their efficacy, lif…
Tirzepatide, a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide 1 (GLP-1) analogue, is a novel medication with comparable pharmacological characteristics and has demonstrated promising weight reduction outcomes in its ant…
IMPORTANCE: Patients with schizophrenia have reduced life expectancy due to cardiovascular disease and obesity-related type 2 diabetes, exacerbated by second-generation antipsychotic (SGA) medication. Existing interventions have shown limited effect.…
BACKGROUND: Glucagon-like peptide‑1 receptor agonists (GLP‑1 RA), such as semaglutide and tirzepatide were originally developed for treatment of type 2 diabetes and have shown significant weight loss effects. This has led to increasing off-label use…
AIMS: To report on the current evidence of early worsening of diabetic retinopathy (EWDR) in patients treated with new-generation antidiabetic agents, with a focus on glucagon-like peptide-1 receptor agonists (GLP1-RA). METHODS: A comprehensive analy…
We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q2-2024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatid…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes (T2D) and weight management, yet their broad health impacts in real-world settings remain understudied. Using data from the All of Us Research Progr…
OBJECTIVE: The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes,…